Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maris

Showing results (191-200 of 458) with videos related to

Pageof 46
Sort By:
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
International Journal of Cancer|August 23, 2018
Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressorFlora Cimmino, Marianna Avitabile, Sharon J Diskin, et al.
American Journal of Respiratory and Critical Care Medicine|July 29, 2008
Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndromeJingtao Huang, Carole L Marcus, Preetam Bandla, et al.
ACS Pharmacology & Translational Science|February 22, 2021
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of GlioblastomaHannah Dabagian, Tahereh Taghvaee, Paul Martorano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay, Jessica C Tan, Judith G Villablanca, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
International Journal of Radiation Oncology, Biology, Physics|February 11, 2019
Outcomes After Proton Therapy for Treatment of Pediatric High-Risk NeuroblastomaChristine E Hill-Kayser, Zelig Tochner, Yimei Li, et al.
Journal of the National Cancer Institute|February 26, 2020
Mitochondrial DNA Haplogroups and Susceptibility to NeuroblastomaXiao Chang, Marina Bakay, Yichuan Liu, et al.
Pediatric Blood & Cancer|July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastomaClarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Pageof 46

Showing results (191-200 of 458) with videos related to

Sort By:
Pageof 46
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
International Journal of Cancer|August 23, 2018
Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressorFlora Cimmino, Marianna Avitabile, Sharon J Diskin, et al.
American Journal of Respiratory and Critical Care Medicine|July 29, 2008
Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndromeJingtao Huang, Carole L Marcus, Preetam Bandla, et al.
ACS Pharmacology & Translational Science|February 22, 2021
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of GlioblastomaHannah Dabagian, Tahereh Taghvaee, Paul Martorano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay, Jessica C Tan, Judith G Villablanca, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
International Journal of Radiation Oncology, Biology, Physics|February 11, 2019
Outcomes After Proton Therapy for Treatment of Pediatric High-Risk NeuroblastomaChristine E Hill-Kayser, Zelig Tochner, Yimei Li, et al.
Journal of the National Cancer Institute|February 26, 2020
Mitochondrial DNA Haplogroups and Susceptibility to NeuroblastomaXiao Chang, Marina Bakay, Yichuan Liu, et al.
Pediatric Blood & Cancer|July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastomaClarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Pageof 46